Investigation of tumor evolution in sporadic and tumor disposition syndrome-associated tumors

Recruiting

• Conditions: tumors in patients with a tumor predisposition syndromesporadic tumors; C00-C97; D00-D09; D10-D36; D37-D48; Malignant neoplasms; In situ neoplasms; Benign neoplasms; Neoplasms of uncertain or unknown behaviour

• Registration Number: DRKS00030089
• Lead Sponsor: niversitätsklinikum Augsburg, Medizinische Fakultät, Universität Augsburg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2022-11-09
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

Diagnosis of one or more tumor diseases (in tumor predisposition or sporadic)

- Treatment in the University Hospital Augsburg or in one of the partner hospitals

- Availability of sufficient tumor material (paraffin material and/or fresh tissue) so that, according to the pathologist in charge, sufficient tumor material is still available for any future diagnostic tests

- Written consent from the patient to participate in the study

Exclusion Criteria

- Insufficient understanding of the German language

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Elucidation of the tumor evolution of tumors in the context of tumor predisposition and in comparison to sporadic tumors.

Secondary Outcome Measures

Name	Time	Method
(1) Description on the therapeutic response to (molecular) therapies as a function of tumor evolution.<br>(2) Identification of genetic changes favoring metastasis.<br>(3) Development of a system for predicting treatment response.<br>(4) Development of a clinical course prediction system.